Positron Emission Tomography (PET)/Computed Tomography (CT) and Roentgen in Lung Cancer: Evaluation of Patients in General Practice (PROLOG)
Recruitment status was Recruiting
The prognosis of lung cancer depends much on the stage of the disease at the time of diagnosis. Only 16 % of lung cancer can be offered curative intended surgery. Chest x-ray is the gate-keeper in lung cancer diagnosis, but it has a miss rate of 20-60 %. A false negative chest x-ray often causes prolonged delay in diagnosis - often months.
Recently a "48 hour diagnosis guaranty" has been implemented, which helps accelerate the system delay (delay from referral to diagnosis). But chest x-ray is still the gate-keeper; if the chest x-ray is negative further examination ceases.
PET/CT has a higher sensitivity (96 %), than chest x-ray. In the latter years only little improvement in the survival rate of lung cancer has been made. Screening studies is currently been performed, but it's time for innovative thinking. PET/CT has established its place in the staging of lung cancer. But studies like this may help to place PET/CT in the chain of examination making it more cost-beneficial.
The overall aim of this study is to improve patient course with earlier diagnosis of lung cancer.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Diagnostic
|Official Title:||PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice|
- Sensitivity and specificity of chest x-ray and PET/CT in Lung Cancer [ Time Frame: min. two years of follow up ] [ Designated as safety issue: No ]
- Positive/negative predictive values of chest x-ray and PET/CT Operability - surrogate for survival Numbers of false positive PET/CT Numbers of false negative PET/CT Numbers of invasive procedures Cost-effectiveness [ Time Frame: min. two years of follow-up ] [ Designated as safety issue: No ]
|Study Start Date:||May 2008|
|Estimated Study Completion Date:||June 2012|
|Estimated Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Radiation: PET/CT (low-dose)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00675168
|Contact: Mie Jung Nielsen, MDfirstname.lastname@example.org|
|Contact: Poul Flemming Højlund Carlsen, MD, Professor, DMSc||0045-6541-2981|
|Department of Nuclear Medicine||Not yet recruiting|
|Odense, Funen, Denmark, 5000|
|Contact: Poul Flemming Højlund Carlsen, MD, Professor, DMSc 45-6541-2981|
|Contact: Allan Johansen, MD, Head of Department 45-6541-2981|
|Principal Investigator: Mie Jung Nielsen, MD|
|Odense, Fünen, Denmark|
|Contact: Nielsen email@example.com|
|Odense, Fünen, Denmark|
|Contact: Nielsen, MD firstname.lastname@example.org|